MPS VII monitoring program for patients and caregivers
Part of Genetic & congenital, Hormones & metabolism, Skin clinical trials.
This trial enrolls people with mucopolysaccharidosis type VII (MPS VII) to track their health over time. It may help your care team better understand how the condition behaves and how monitoring should be done.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have lab-confirmed MPS VII (either an enzyme test or a gene/mutation test).
- You (or your legal representative) can give written consent to join.
- If you are under 18 (or have cognitive difficulties), you can provide assent if required, plus consent from a legal representative.
- You are willing to follow the study visit schedule for monitoring.
- You are not currently in another drug study run by a different pharmaceutical company (unless Ultragenyx approves it).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study follows people with MPS, a rare genetic condition, to learn more about the disease over time. If you have a confirmed MPS diagnosis, you may be able to join.
This program provides access to Mepsevii, an enzyme replacement therapy, for people with MPS VII who cannot get the drug through their regular healthcare system. It is a way to try the treatment outside of a clinical trial.
This study is a registry that collects information from people diagnosed with lysosomal storage diseases. It helps researchers better understand these conditions and support future studies.
This Phase 1 trial tests an enzyme replacement treatment given to a developing baby before birth for specific inherited “lysosomal storage” diseases. The goal is to see if the treatment is safe and can improve outcomes for babies diagnosed in pregnancy.
This study follows participants who previously received the RGX-111 treatment to monitor their health over time. It helps researchers understand the long-term effects and safety of the therapy.
This study follows people with MPS IIIC over time to learn more about how the disease progresses. It does not test a new treatment, but the information may help with future care and research.
Hear when a new Mucopolysaccharidosis VII trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.